Why Has Japan Launched A $420m Fund For Bioventures?
Application For VCs Opened In Ecosystem Bid
Executive Summary
A new national project to support bioventures and the venture capital funds investing in them has started in Japan. The strategic aim of the JPY50bn initiative is to enhance the speed of development and trials of new drugs and vaccines for infectious diseases, the lack of which became obvious since the breakout of COVID-19.
You may also be interested in...
SCARDA: Japan’s New Vaccine R&D Center With $1.6bn Budget – But Where's The Goal?
Japan has launched a new center to support vaccine and drug projects as a part of a larger scheme to tackle infectious disease. SCARDA will be in charge of establishing a flagship R&D site for innovative collaborations and controlling funds for R&D projects.
Beyond Next Aims To Boost Bioventures Over Japan Hurdles
Set up to support the development of bioventures in Japan, Tokyo’s Beyond Next Ventures sees itself as a broad-benefit accelerator able to work with a wide range of partners to help discover and develop life science innovation, in an environment that still presents challenges.
Texas To Tokyo: Japan Darvias Approval Marks End Of Long Development Road
Solasia's arsenical drug darinaparsin has received its global-first approval in Japan, for PTCL, in a landmark for the Texan chemist who discovered it back in the 70s and paving the way for wider indications and Asian markets.